Ask AI
ProCE Banner Activity

LEN PrEP Utilization in Real-world US Settings

Conference Coverage
Slideset

This epidemiologic study characterized early utilization of injectable lenacapavir PrEP in real-world US settings during the first 9 months after FDA approval. Investigators report LEN utilization among a diverse population of individuals, including women, people with no previous PrEP experience, and people with prior oral and injectable PrEP experience.

Released: October 27, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Integrate the latest scientific findings to develop and optimize effective HIV prevention interventions